Albireo Pharma, Inc
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
53 State St Fl 19, Boston, Massachusetts...Phone Number
(857) 254-5555Website
www.albireopharma.comRevenue
$43.5 MillionStock Symbol
ALBOIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Albireo Pharma, Inc
Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. Albireo is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden.Explore more
Albireo Pharma, Inc Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Albireo Pharma, Inc your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Albireo Pharma, Inc recently announced quarterly report
Check if Albireo Pharma, Inc has recently received funding, and reach out quickly before it becomes old news!
Check out if Albireo Pharma, Inc is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Albireo Pharma, Inc
Albireo Pharma, Inc, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Albireo Pharma, Inc had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Albireo Pharma, Inc has new funding data
Product Launch: Get notified when Albireo Pharma, Inc launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Albireo Pharma, Inc as Masked Content
Find 2 more new buyers
Compare Similar Companies to Albireo Pharma, Inc
Compare insights from companies similar to Albireo Pharma, Inc, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Albireo Pharma, Inc is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Albireo Pharma, Inc is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Albireo Pharma, Inc.
Albireo Pharma, Inc financials insights
Gather financial insights about Albireo Pharma, Inc, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Private Equity
$115M
Albireo Pharma, Inc Tech Stack
A closer look at the technologies used by Albireo Pharma, Inc
See more technologies
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions
Open Position
Open Position
New Hire
Executive Move
Executive Moves, New Hire
Albireo Pharma, Inc News & Media
FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille Syndrome
Bylvay (odevixibat) granted Priority Review by U.S. FDAASSERT study demonstrated efficacy of Bylvay in pruritus, bile acids and sleep with a low drug-related diarrhea rate in Alagille patientsApproval in second indication would more than double Bylvay market opportunity BOSTON, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced that the U.S. Food and DrugSHAREHOLDER ALERT: Weiss Law Reminds ALBO, CINC, DCT, and PAYA Shareholders About Its Ongoing Investigations
NEW YORK, Jan. 16, 2023 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. Weiss Law 305 Broadway, 7th Floor New...SHAREHOLDER ALERT: Weiss Law Investigates Albireo Pharma, Inc.
NEW YORK, Jan. 9, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Albireo Pharma, Inc. ("Albireo" or the "Company") (NASDAQ: ALBO), in connection with the proposed acquisition of the Company by...ALERT: The M&A Class Action Firm Announces the Investigation of Albireo Pharma, Inc. - ALBO
NEW YORK, Jan. 9, 2023 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Albireo Pharma, Inc
Sign Up For FreeTo access detailed company insights
Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. Albireo is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden.... Read More
